Flemington, New Jersey based clinical stage biopharmaceutical company Arno Therapeutics, Inc. has announced data from a preclinical study demonstrating that its drug candidate AR-13, an analogue of Arno’s AR-12 infectious disease compound portfolio, shows promise as a potential new therapeutic option for patients with cystic fibrosis (CF) who are…
News
Two clinical-stage companies with investigational products for the cystic fibrosis treatment market have just announced their attendance and participation at the upcoming Leerink Partners’ 4th Annual Rare Disease Roundtable, taking place on Wednesday, September 30, 2015 at the Le Parker Meridien in New York, NY. The conference’s attendees will watch presentations on product and investment-related…
Concert Pharma recently announced successful results from a Phase 1 single ascending dose clinical trial for their lead investigational drug CTP-656 as a therapy for cystic fibrosis. Cystic fibrosis is a life-threatening disease characterized by a progressive lung function decline and is caused by mutations in the Cftr gene (cystic fibrosis transmembrane…
Not long after his birth in 2013, Paul Siebenthal‘s son Noah was diagnosed with cystic fibrosis (CF) and the new father became aware that his son would struggle with a chronic, life-threatening disease for his entire life. However, Paul Siebenthal did not accept that there is currently no cure for the…
Peter and Mary Frey are a young couple just like any other, starting a family together. However, there is one thing that makes their family different from the average American household. Mary suffers from cystic fibrosis (CF), a genetic and chronic disease that causes the excessive production of mucus in the lungs,…
The 2015 UK Cystic Fibrosis Conference (UKCFC), the United Kingdom’s most-anticipated annual conference for the cystic fibrosis community that brings together esteemed disease experts, researchers, health professionals, patients and family members, is set to take place on September 22-23, 2015. The two-day event is expected to attract over 300 attendees to Manchester, UK for…
Johns Hopkins University Hospital physician and Cystic Fibrosis Foundation Vice President of Therapeutics Development Michael Boyle, M.D., testified on Friday, September 18th before the House Energy and Commerce Committee’s on Health, urging Subcommittee members to support Bill H.R. 209, which would make a permanent the Ensuring Access to Clinical…
Arch Biopartners Inc (Arch), recently announced that its drug candidate AB569, which is being developed as treatment for pulmonary Pseudomonas aeruginosa infections, has successfully concluded pre-clinical in vivo and in vitro validation trials. The news is significant to the CF community due to the prevalence of P. aeruginosa in those with…
ProQR Therapeutics, a Leiden, NL based biotech company focused on development of drugs to treat severe genetic disorders, recently announced that its PQ-010-002 clinical trial is open for patient enrollment. The study’s primary endpoint is the estimation of the effect of topical administration of QR-010 on the nasal mucosa…
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ (inhaled small particles easily respirable and emitted) technology, has just announced it will be presenting preclinical data on the pharmacokinetics and potency of PUR1900 during the upcoming 2015 North American Cystic Fibrosis Conference. PUR1900 is an…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.